The endovascular management of intracranial vascular disease including the MERCI device

被引：2

作者：

Gandhi C.D. ^{[1
]}

Johnson D.M. ^{[1
]}

Patel A.B. ^{[1
]}

机构：

[1] Department of Neurosurgery, The Mount Sinai School of Medicine, New York, NY 10029-6574, 1 Gustave Levy Place

来源：

Current Cardiology Reports | 2007年 / 9卷 / 1期

关键词：

Acute Stroke; Acute Ischemic Stroke; Basilar Artery; Abciximab; Basilar Artery Occlusion;

D O I：

10.1007/s11886-007-0006-9

中图分类号：

学科分类号：

摘要：

The prompt and aggressive management of acute stroke has become the standard of care as public awareness and the available successful treatment options both increase. The intravenous administration of tissue plasminogen activator within an established treatment window has been determined through large well-designed studies. The endovascular strategies for acute stroke have evolved significantly over the past 5 years and have been prompted by the limits of the intravenous treatment, as well as by the desire to demonstrate improved recanalization rates and improved long-term outcomes. Among these interventional treatment options are the intra-arterial administration of tissue plasminogen activator and newer antiplatelet agents, mechanical thrombectomy with the MERCI device, and intracranial angioplasty and stenting. This article outlines the major studies that have defined the current field of acute stroke management and discusses the basic treatment paradigms that are commonly utilized today. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：25 / 31

页数：6

共 39 条

[1]

Heart and Stroke Facts Statistics: 1999 Statistical Supplement, (1999)

[2]

Chambers B.R., Norris J.W., Shurvell B.L., Hachinski V.C., Prognosis of acute stroke, Neurology, 37, pp. 221-225, (1987)

[3]

Saito I., Segawa H., Shiokawa Y., Et al., Middle cerebral artery occlusion: Correlation of computed tomography and angiography with clinical outcome, Stroke, 18, pp. 863-868, (1987)

[4]

Sacco R.L., Kargman D.E., Gu Q., Zamanillo M.C., Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study, Stroke, 26, pp. 14-20, (1995)

[5]

Schellinger P.D., Fiebach J.B., Mohr A., Et al., Thrombolytic therapy for ischemic stroke - A review. Part I - Intravenous thrombolysis, Crit Care Med, 29, pp. 1812-1818, (2001)

[6]

Higashida R.T., Furlan A.J., Roberts H., Et al., Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke, Stroke, 34, (2003)

[7]

Tissue plasminogen activator for acute ischemic stroke, N Engl J Med, 333, pp. 1581-1587, (1995)

[8]

Labiche L.A., Al-Senani F., Wojner A.W., Et al., Is the benefit of early recanalization sustained at 3 months? A prospective cohort study, Stroke, 34, pp. 695-698, (2003)

[9]

Haley Jr. E.C., Lewandowski C., Tilley B.C., Myths regarding the NINDS rt-PA Stroke Trial: Setting the record straight, Ann Emerg Med, 30, pp. 676-682, (1997)

[10]

Felberg R.A., Okon N.J., El-Mitwalli A., Et al., Early dramatic recovery during intravenous tissue plasminogen activator infusion: Clinical pattern and outcome in acute middle cerebral artery stroke, Stroke, 33, pp. 1301-1307, (2002)

← 1 2 3 4 →